1.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 25 to 75 Sponsor: Other Protocol IDs: O2006-415, NCT00375661
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C98-026, SPRI-C98-026-054, SPRI-I98-026
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P04831, NCT00457418
|
|
4.
|
Phase: Phase III Type: Treatment Status: Closed Age: 5 to 40 at diagnostic biopsy Sponsor: NCI Protocol IDs: COG-AOST0331, AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-01143, NCI-G-02-2102, NCT00045279
|
|
6.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-2602, E2602, NCT00049530
|
|
7.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 030002, 03-C-0002, NCI-03-C-0002, NABTC-0201, NCT00052650, NCT00047879
|
|
8.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-02063, NCI-4772, NCT00055809, 4772
|
|
9.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000378049, MUSC-100614, CELGENE-MUSC-100614, MUSC-HR-10423, NCT00090870
|
|
10.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-02033A
|
|
11.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000441020, MDA-ID-01450, NCT00276523
|
|
12.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000445593, WSU-C-2257, WSU-HIC-120900M01-FB, NCT00238329
|
|
13.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2006-0360, NCT00415857
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000540598, P30CA093373, CCC-PHII-40, ZENECA-AZ1839US/0227, UCD-200412338-4, UCD-ZD1839, PHII-40, NCT00467077
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0143, NCT00525031
|
|
16.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: DeCOG SoraPeg 2007, EudraCT 2007-001918-16, NCT00623402
|
|
17.
|
Phase: Phase II Type: Treatment Status: Closed Age: 19 and over Sponsor: Other Protocol IDs: USA-MCI-01, IND# 13647, NCT00746746
|
|
18.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068523, DMS-0010, NCI-G01-1924, NCT00014261
|
|
19.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NVCI-0725, NVCI 07-25, 8224, NCT00701298
|
|
20.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2006-0816, NCT00861406
|
|
21.
|
Phase: No phase specified Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: ID02-534, NCT00050531
|
|
22.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EPROST-20070805, SCCC-2007055, NCT00854581
|